GH Research Q3 2024 Results and Clinical Updates
Gh Research Plc ( (GHRS) ) has released its Q3 earnings. Here is a breakdown of the information Gh Research Plc presented to its ...
Medication mimicking alcohol may benefit laryngeal dystonia patients
Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to ...
thecardiologyadvisor.com11m
Tirzepatide Promising for Patients With HFpEF and Obesity
Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...
labiotech57m
Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024
The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...
Opinion - We have a chronic disease epidemic because government has fattened us up
Donald Trump's return to the White House presents an opportunity to overhaul federal dietary guidelines, which lack ...
Daily58m
Novel Oral Drug Muvalaplin Lowers Lipoprotein (a) Levels: Clinical Trial Findings
A late-breaking clinical trial has shown that muvalaplin, an innovative oral medication, can safely and effectively lower ...